Scancell Share Discussion Threads

[888icb] 15/7/2024 09:17

Good to see a 200000 Buy at 11.7p which is a £23400 vote of confidence in the first few minutes of trading this morning. Let’s hope the recovery continues and SCLP is soon pushing above 12p and on its way to a much higher level.

[a0469514] 14/7/2024 22:52

That's a bit harsh on Lozan. I quite like the sound of his lifestyle.Xylos

[plasybryn] 14/7/2024 18:03

OTC Markets:- share price went up 26% on Friday, equivalent to 12.75p.https://www.otcmarkets.com/stock/SCNLF/overview

[inanaco] 13/7/2024 18:27

whats boring loz about watching the French Elections and them playing football

[plasybryn] 13/7/2024 17:35

This presentation was given in May https://www.youtube.com/watch?v=TodDgfpBjjA

[inanaco] 13/7/2024 16:12

we have the products .............

Immunobody proves "high Avidity" T cells work

Moditope will prove a Cytotoxic CD4 is potent

Glymab will prove Sugars as a target ...

Folks have to stop thinking small ......

[inanaco] 13/7/2024 16:09

still way to cheap we have to trial a Glymab and Homocitrulline which is more potent than Modi1

[markingtime] 13/7/2024 15:31

I was thinking, whilst out just now, that a deal might be do-able that provided some major funding (eg from BMS) in exchange for an option to buy the whole company in 2026/7 at, say, £6 a share. Obviously that would be at a discount to some valuations....but it would lower the risk to both sides......

[inanaco] 13/7/2024 14:55

If you think about it .............

why would we need to trial in Ovarian ?

if Bristol Myers likes what we have done in Renal Cancer with Checkpoints

why would they not fund the trial at no cost to us ? after all its an indication they would love to access


Give that some thoughts !!

[inanaco] 13/7/2024 14:10

the disaster unfolding ...........

Left wing f##k wits in the UK and France ..... in charge

until they run out of "other peoples money"

[inanaco] 13/7/2024 14:06

Labour is busy closing the Oil fields and stopping the new coal mine that is required for steel production ....

despite our need for steel and we use Gas to generate 74% of electricity ...

the wind will always blow ... PMSL

so the uk green fields will be covered with Wind Mills and council houses ... and the beaches ... rubber dingy's

Growth ... ?

oh and tax North sea to 78% while closing it down

another black hole to fill

Capital Gains tax any one ?

[rogerbridge] 13/7/2024 14:05

RE: posts above.

Moditope is the reverse

so in Ovarian Cancer the checkpoints hardly made a difference a cold cancer but Moditope has, so now its role reversed

checkpoints assist the vaccine.



There will be be seveal companies wanting a slice of this if the data is confirmed.
It could be A HUGE MARKET!

[markingtime] 13/7/2024 13:41

Some of your best points ever in those two posts, inanaco. These are the reasons for Lindy's closing comments in the recent interview. The IP protection for the suite of cancer solutions provided by Scancell should be extremely valuable - and because their approach is unique there is little direct threat from competitors (at present, anyway).What is needed is to move these treatments on at pace, so that patient benefits can be achieved quickly. I hope the new Labour government is watching closely.

[inanaco] 13/7/2024 12:36

when Scancell announced the Moditope data many thought it had not worked as it should
so sold down

but that was the wrong decision because we had a response, we had t cells which means you are 80% there ... all we have to do is find out what was blocking them ...

so I added another 500,000 shares also knowing that SCIB1 had my back ....

answer coming very soon and the recent poster by scancell gives you a good insight ...

T regulatory CD4 which suppress a moditope CD4

CTL-4 suppresses regulatory T cells

moditope plus Pd-1 and Ctl-4

could be the game changer

remember all patients had a response from the vaccine .....

the share price is extremely low

only YOU can act on it

[inanaco] 13/7/2024 12:16

Marcus this is what Investors don't quite understand

Scib1 was never designed for solid cancer but adjuvant melanoma after surgery

but it was so good some patients with solid cancer had a response

but because melanoma is a hot cancer the checkpoints also worked on there own and quite successfully add SCIB1 synergy and it really works well

so checkpoint assisted by vaccine

Moditope is the reverse

so in Ovarian Cancer the checkpoints hardly made a difference a cold cancer but Moditope has, so now its role reversed

checkpoints assist the vaccine

To put this into context

It opens a NEW Market for the checkpoints ............in cold cancers


Dont lose sight of that because the competition in the checkpoint market is huge as all the majors are in

if you understand Markets .......... that's Boom for the checkpoints

But only one Moditope

all about the number you hold ...

Study Cold cancers
Study Checkpoint failure in cold cancers

and understand every solid cancer has autophagy = moditope

or

Glymabs another PTM

There are over 15 different glycans commonly added to glycoproteins or glycolipids, either sequentially or in branched formats. This glycosylation, commonly referred to as the cellular “glycome”; and executed by a combination of intricately regulated enzymes, undergoes dramatic changes during malignant transformation, leading to the generation of many unique cancer targets.

you have to start applying multipliers scancell is NOT restricted in finding more Glymabs

or Moditope

[marcusl2] 13/7/2024 09:56

The aim of the study was to see whether the vaccine could either induce new, or boost existing, immune responses. These responses could then be protected in the tumor environment by checkpoint inhibitors—in this case Bristol Myers Squibb’s Opdivo and Yervoy.

Patients received SCIB1 via a needle-free device. The company is aiming to beat the 50% ORR of the Opdivo-Yervoy combo alone.



Merck Pembrolizumab, sold under the brand name Keytruda Key patent expiration: 2028 $33.7bn in 2028

Bristol Myers Squibb’s Ipilimumab (Yervoy®) patents will expire in the US in 2023 sales $2.2bn

Bristol Myers Squibb’s Opdivo (nivolumab) Key patent expiration: 2028 sales are predicted to reach $11.75 billion by 2026

[marcusl2] 12/7/2024 22:14

The fire and ice of oncolytic virotherapy


The Moditope platform exploits and harnesses the normal immune response that uses cytotoxic CD4 T cells to eradicate stressed cells. Citrullinated or homocitrullinated peptides are directly conjugated to adjuvant to activate APCs and allow presentation on MHC IIs to killer CD4 T cells. These primed killer CD4 T cells infiltrate the TME where they initially encounter citrullinated or homocitrullinated peptides expressed on the surface of APCs which stimulates release of interferon gamma (IFNγ), which induces local inflammation and upregulation of MHC-II on tumour cells. Tumour cells typically create an anti-inflammatory microenvironment, where MHC II expression is not upregulated, to evade the immune system.

The secretion of IFN-ϒ and the resultant inflammation could alter the nature of the TME, effectively converting “cold” tumours into “hot” ones, and so make a tumour visible to other elements of the immune system. Hence, Moditope stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise remain hidden from the immune system. This suggests Moditope offers the scope to be used alone, or in combination with other agents (including checkpoint inhibitors), to treat a wide range of currently hard to treat cancers.

[marcusl2] 12/7/2024 22:13

Moditope could be the crown jewels.

16 patients scanned and 7 stable
responses by RECIST (44%). Stable disease
= between 20% and -30% change in target
lesion size with no new lesions present

► Data similar to monotherapy SCIB1 in
unresected patients

► Should see stronger responses in
combination with CPIs particularly antiPD1 and anti-CTLA4 but these are not
approved for ovarian cancer

► Show syngery with Modi-1 and anti-PD1
in H&N cancer

► consider a new cohort with HCC where
the double CPIs are indicated and then
persuade pharma to combine Modi-1
with double CPIs in ovarian cancer

Dr David Pinato, Principal Investigator at Imperial College, commented:
“Advanced ovarian cancer is an aggressive cancer which is hard to treat. A disease control rate of 44% with Modi-1 in patients who have exhausted most treatment options is very encouraging”.

[the real lozan] 12/7/2024 18:16

All Oak logs -
Delivered, bought and paid for, in and stacked to burn in 18 / 24 months time
Time for a well earned beer

[markingtime] 12/7/2024 16:45

All the valuations exclude quite a bit of potential upside, so I'd take numbers with a pinch of salt. Only the market for corporate deals is relevant - and I suspect that will soon be materially higher, once the reasons for Lindy's interview confidence becomes clear.

[888icb] 12/7/2024 16:23

We need to double to get to Morningstar and triple to get to Trinity Delta. Personally I think they are both very light particularly if news of a big deal drops.
One thing is undeniable and that is SCLP is massively undervalued. We are clearly in the best place we have ever been but we are no where near are 18p high of the year and are 50% down on where we were 3 years ago. SCLP signed deals a couple of years ago that can bring in upto $600 million plus royalties but still the market cap is only £100 million.

[marcusl2] 12/7/2024 15:40

Trinity Delta valuation for Scancell is £304m, or 33p per share.